Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size

Trial Profile

Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size

Completed
Phase of Trial: Phase II

Latest Information Update: 25 May 2016

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Thymoma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
    • 24 Nov 2014 Planned End Date changed from 1 Dec 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 24 Nov 2014 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top